Skip to content
Synopulse
  • The Brief
    • Quick
    • In Depth
    • Editor’s Pick
    • Findings
  • Reports
    • The beats
      • Catalyst
      • AccessWatch
      • DealPulse Signal
      • DealPulse Report
    • Analysis
      • The Throughline
      • The Top Line
      • The Forecast
    • Coverage
      • ShowFloor
      • The Arena
  • The Pulse
    • NeuroPulse
    • OrphanPulse
  • Topics
    • By subject
      • Deals
      • Regulatory
      • Market Access
      • Pricing & Reimbursement
      • Legal & Policy
    • By technology
      • Antibody
      • Cell & Gene Tx
      • Drug conjugates
      • AI/ML
      • Digital Health
      • Radiopharma
    • By therapy area
      • Neurology
      • Oncology
      • Rare Diseases
      • Cardio-Metabolic
      • Immunology & Inflammation
      • Orthopaedics

Sandoz

Biocon Makes It, a Consultancy Holds the Licence, and Sandoz Sells It

August 28, 2026 by Athithi Verma
Biocon Makes It, a Consultancy Holds the Licence, and Sandoz Sells It

Three parties, three functions, and Biocon holds only the middle one. Treat the caretaker MAH structure as the Japanese default, not the exception.

Categories Approval, CI read, Oncology, Peptide, Quick, The Brief Tags Amgen, Biocon, Biosimilars, India, Japan, Market Access, MHLW, Pegfilgrastim, Sandoz

The EPO Revoked BMS’s 480mg Opdivo Patent Because the Trial Behind It Dosed by Weight

August 6, 2026 by Athithi Verma
The EPO Revoked BMS's 480mg Opdivo Patent Because the Trial Behind It Dosed by Weight

BMS claimed a 480mg flat dose. The only clinical example in its filed application dosed by weight. The EPO revoked the patent on added matter.

Categories Antibody, CI read, Legal & Policy, Oncology, Quick, The Brief Tags Amgen, Biosimilars, Bristol-Myers Squibb, EPO, Europe, nivolumab, OPDIVO, Patent opposition, PD-1, Sandoz

Brazil Approved Five Semaglutides in a Day. Sandoz Announced One of Them.

July 30, 2026 by Athithi Verma
Brazil Approved Five Semaglutides in a Day. Sandoz Announced One of Them.

ANVISA approved five semaglutide products in a single day, including the one Sandoz will sell. Ozempic’s Brazilian patent expired in March.

Categories Access Read, Cardio-Metabolic, Peptide, Quick, The Brief Tags Adalvo, ANVISA, Brazil, Generics, GLP-1, LATAM, Market Access, Novo Nordisk, Owozy, Ozempic, Sandoz, semaglutide

Trump Wants Generics Made in America by 2028. The Economics Say They Can’t.

July 23, 2026 by Athithi Verma
rump Wants Generics Made in America by 2028. The Economics Say They Can't.

Trump gave generic drugmakers until August 2028 before a 100% tariff, rising to 200% in 2029. The problem is the margin those drugs actually carry.

Categories Access Read, In Depth, Legal & Policy, Market Access, The Brief Tags Apotex, Drug shortages, Generics, India, Sandoz, Supply Chain, Tariffs, Teva, Viatris
Synopulse Weekly Pulse: Access Decisions, Regulatory Events & Market Dynamics, Week of Nov 24 2025

Synopulse Weekly Pulse – November 24, 2025

Read Now
  • Access Read
  • AI/ML
  • Analysis
  • Antibody
  • Approval
  • Cardio-Metabolic
  • Cell & Gene Tx
  • CI read
  • Clinical Read
  • Coverage
  • Deal Read
  • DealPulse
  • DealPulse Report
  • DealPulse Signal
  • Deals
  • Diagnostics
  • Digital Health
  • Drug conjugates
  • Drug Repurposing
  • Editor's Pick
  • Findings
  • Immunology & Inflammation
  • In Depth
  • Launch
  • Legal & Policy
  • Market Access
  • MedTech
  • Neurology
  • NeuroPulse
  • News
  • Oncology
  • Ophthalmology
  • Organ On Chip
  • OrphanPulse
  • Orthopaedics
  • Peptide
  • Pricing & Reimbursement
  • Pulmonology
  • Quick
  • Radiopharma
  • Rare Diseases
  • Regulatory
  • Reports
  • RNA
  • Science Read
  • ShowFloor
  • Small Molecule
  • The beats
  • The Brief
  • The Pulse
  • The Throughline
  • The Top Line
  • September 2026
  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • March 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • July 2025
  • June 2025
  • February 2025
  • January 2025
  • October 2024
  • September 2024
Synopulse
Contact Us

Explore Synopulse

  • NeuroPulse
  • Deals
  • Market Access
  • Industry Trends
  • Regulatory

About

  • About Synopulse
  • Contact Us
  • Announcements
© 2026 Synopulse • Built with GeneratePress